Related Experiment Video
Updated: Jul 15, 2025

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer
Published on: February 13, 2019
Sustained Increases in Cardiomyocyte Protein O-Linked β-N-Acetylglucosamine Levels Lead to Cardiac Hypertrophy and
Chae-Myeong Ha1, Sayan Bakshi1, Manoja K Brahma1
1Division of Molecular and Cellular Pathology, Department of Pathology University of Alabama at Birmingham Birmingham AL.
Insights
Sustained protein O-GlcNAcylation in heart cells initially reduces metabolic pathways but leads to cardiac remodeling and diastolic dysfunction over time. This study reveals adaptive vs. maladaptive responses to O-GlcNAcylation in the heart.
Area of Science:
- Cardiovascular Disease Research
- Metabolic Regulation
- Posttranslational Modifications
Background:
- Metabolic diseases and lifestyle factors significantly impact cardiovascular disease (CVD) pathogenesis.
- Posttranslational modifications, such as O-linked β-N-acetylglucosamine (O-GlcNAcylation), play a role in physiological and pathological adaptations.
- O-GlcNAcylation is implicated in the molecular mechanisms underlying cardiac function and dysfunction.
Purpose of the Study:
- To investigate the hypothesis that sustained protein O-GlcNAcylation in cardiomyocytes contributes to cardiac adaptations.
- To determine how O-GlcNAcylation progression leads from adaptation to pathophysiology.
- To explore the differential responses of cardiac metabolism and function to increased O-GlcNAcylation.
Main Methods:
- Utilized a cardiomyocyte-specific inducible transgenic mouse model overexpressing dominant-negative O-GlcNAcase (dnOGA).
- Examined effects of 2-week and 24-week dnOGA overexpression on cardiac structure and function.
- Conducted mRNA-sequencing to analyze gene expression changes related to metabolism and cardiovascular disease.
Main Results:
- 24-week dnOGA overexpression led to a 1.8-fold increase in protein O-GlcNAcylation.
- Cardiac hypertrophy, mitochondrial dysfunction, fibrosis, and diastolic dysfunction were observed after 24 weeks.
- Systolic function was maintained, but gene expression showed reduced mitochondrial oxidative phosphorylation, fatty acid/glucose metabolism, and antioxidant pathways.
Conclusions:
- Moderate increases in cardiomyocyte O-GlcNAcylation induce an initial reduction in metabolic pathways, followed by cardiac remodeling.
- The mouse model exhibited diastolic dysfunction, consistent with heart failure with preserved ejection fraction (HFpEF).
- Findings offer insights into adaptive and maladaptive responses to elevated O-GlcNAcylation in the heart.
Abstract:
Background Lifestyle and metabolic diseases influence the severity and pathogenesis of cardiovascular disease through numerous mechanisms, including regulation via posttranslational modifications. A specific posttranslational modification, the addition of O-linked β-N acetylglucosamine (O-GlcNAcylation), has been implicated in molecular mechanisms of both physiological and pathologic adaptations. The current study aimed to test the hypothesis that in cardiomyocytes, sustained protein O-GlcNAcylation contributes to cardiac adaptations, and its progression to pathophysiology. Methods and Results Using a naturally occurring dominant-negative O-GlcNAcase (dnOGA) inducible cardiomyocyte-specific overexpression transgenic mouse model, we induced dnOGA in 8- to 10-week-old mouse hearts. We examined the effects of 2-week and 24-week dnOGA overexpression, which progressed to a 1.8-fold increase in protein O-GlcNAcylation. Two-week increases in protein O-GlcNAc levels did not alter heart weight or function; however, 24-week increases in protein O-GlcNAcylation led to cardiac hypertrophy, mitochondrial dysfunction, fibrosis, and diastolic dysfunction. Interestingly, systolic function was maintained in 24-week dnOGA overexpression, despite several changes in gene expression associated with cardiovascular disease. Specifically, mRNA-sequencing analysis revealed several gene signatures, including reduction of mitochondrial oxidative phosphorylation, fatty acid, and glucose metabolism pathways, and antioxidant response pathways after 24-week dnOGA overexpression. Conclusions This study indicates that moderate increases in cardiomyocyte protein O-GlcNAcylation leads to a differential response with an initial reduction of metabolic pathways (2-week), which leads to cardiac remodeling (24-week). Moreover, the mouse model showed evidence of diastolic dysfunction consistent with a heart failure with preserved ejection fraction. These findings provide insight into the adaptive versus maladaptive responses to increased O-GlcNAcylation in heart.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure II: Pathophysiology
Myocarditis I: Introduction
Proteoglycans
Heart Failure Drugs: Inotropic Agents
Cardiomyopathy II: Dilated Cardiomyopathy

